These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27610197)

  • 1. Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer.
    Murray NP; Aedo S; Reyes E; Fuentealba C; Jacob O
    Ecancermedicalscience; 2016; 10():671. PubMed ID: 27610197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
    Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
    Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Dueñas R
    Arch Esp Urol; 2014 Oct; 67(8):684-91. PubMed ID: 25306986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3375-3381. PubMed ID: 30583343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
    Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1577-1583. PubMed ID: 29936782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    Murray NP; Aedo S; Reyes E; Orellana N; Fuentealba C; Jacob O
    BJU Int; 2016 Oct; 118(4):556-62. PubMed ID: 26507242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
    Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Bádinez L; Olivares R; Porcell J; Dueñas R
    ScientificWorldJournal; 2013; 2013():762064. PubMed ID: 23653529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the Presence of Primary Circulating Prostate Cells Imply the Presence of Agressive Prostate Cancer with Early Biochemical Failure: a Comparison with the Walz Nomogram.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Orellana S; Jacob O
    Asian Pac J Cancer Prev; 2016; 17(7):3089-93. PubMed ID: 27509934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How localized is pathologically localized prostate cancer? The use of secondary circulating prostate cells as a marker of minimal residual disease and their association with patient outcome.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
    Turk J Urol; 2017 Dec; 43(4):456-461. PubMed ID: 29201508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
    Asian Pac J Cancer Prev; 2018 Jan; 19(1):229-236. PubMed ID: 29374406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(16):7123-7. PubMed ID: 26514500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer.
    Murray NP; Reyes E; Salazar A; Lopez MA; Orrego S; Guzman E
    Turk J Urol; 2020 May; 46(3):186-195. PubMed ID: 32401703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Ecancermedicalscience; 2020; 14():1042. PubMed ID: 32565895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Ecancermedicalscience; 2019; 13():934. PubMed ID: 31281431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
    Ecancermedicalscience; 2018; 12():844. PubMed ID: 30034521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence.
    Murray NP; Reyes E; Fuentealba C; Jacob O; Orellana N
    Asian Pac J Cancer Prev; 2015; 16(15):6615-9. PubMed ID: 26434884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.
    Stamey TA; Yemoto CM; McNeal JE; Sigal BM; Johnstone IM
    J Urol; 2000 Apr; 163(4):1155-60. PubMed ID: 10737486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.